The PROTECT Study: Clinical and Biological Predictors of Chemotherapy Response in Older Adults

The goal of this study is to help doctors predict which patients 65 years and above are more likely to tolerate chemotherapy for stages I to III breast cancer with minimal side effects. Dr. Gross is PI at Yale, which is one of ten sites participating in this research project coordinated by City of Hope National Medical Center in California. We plan to enroll a total of 40 women at Yale as part of 500 women who will participate in the study.  www.clinicaltrials.gov ID= NCT01472094